Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry

BACKGROUND: Biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARD) are widely used for treatment of rheumatoid arthritis (RA), enabling patients to better achieve remission. OBJECTIVE: The objective of the study was to investigate and compare remission rates in RA patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Koh, Jung Hee, Lee, Yusun, Kim, Hyoun-Ah, Kim, Jinhyun, Shin, Kichul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109493/
https://www.ncbi.nlm.nih.gov/pubmed/35586514
http://dx.doi.org/10.1177/1759720X221096363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109493/
https://www.ncbi.nlm.nih.gov/pubmed/35586514
http://dx.doi.org/10.1177/1759720X221096363

Ejemplares similares